Trifarotene Aklief denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for trifarotene aklief are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for Trifarotene (Aklief)

Aklief (trifarotene) is a branded topical retinoid, and Aetna places branded dermatology medications in a tier that requires prior authorization before the claim will be paid. The PA requirement exists because Aetna wants to confirm that lower-cost formulary alternatives — typically generic topical retinoids — have been tried and found inadequate before the plan covers a more expensive branded option. A PA denial most often means the submission lacked the clinical documentation to satisfy each of Aetna's stated criteria, not that the drug is categorically unavailable under the plan.

## Why a PA Denial Is Appealable

Prior authorization criteria must be based on evidence-based clinical standards, and Aetna must grant approval when those standards are met. If your dermatologist has documented the diagnosis, prior treatment history, and clinical rationale for trifarotene, a complete appeal submission can satisfy every PA criterion that the initial request may have left unaddressed.

## Your Federal Appeal Rights

• Internal appeal: File within the timeframe shown on your EOB. Submit the full clinical package — not just the PA form. Aetna must respond within the applicable regulatory deadline.
• External review (ACA §2719): After an internal appeal denial, you may request independent external review, typically within about four months of the original denial. The IRO reviews the clinical record on its merits, independent of Aetna's policies.
• ERISA §503: If your plan is employer-sponsored, you are entitled to a full-and-fair review, including all clinical-policy documents and reviewer notes used in the PA determination.
• Expedited review: Available when standard review timelines would cause significant health harm — a decision is typically required within 72 hours.

## Documentation to Gather

• Diagnosis confirmation: Dermatologist's chart notes confirming acne vulgaris diagnosis with documented severity and affected areas.
• Prior topical retinoid history: A complete medication history showing every formulary retinoid previously tried — tretinoin, adapalene, or other covered agents — with start/end dates and the specific reason each was discontinued (inadequate clearance, tolerability issues, or documented contraindication).
• Current clinical status: Recent chart notes reflecting current disease burden and the treating dermatologist's assessment.
• Prescriber medical-necessity letter: A letter from your dermatologist specifically addressing each of Aetna's PA criteria, explaining why trifarotene is the medically appropriate choice, and referencing applicable AAD guideline direction (without citing specific numerical thresholds).
• Aetna's PA criteria: Request the exact criteria; you are entitled to them under ERISA or state law.

## Criteria-Mapping Structure

Obtain Aetna's PA criteria for trifarotene or the topical retinoid class. Then map each criterion to a specific chart document:

| Aetna PA Criterion | Status | Supporting Evidence | |---|---|---| | Acne vulgaris diagnosis confirmed | Met | Chart note [date] | | Prior formulary retinoid tried | Met | Medication record + chart note with outcome | | Prior retinoid inadequate or not tolerated | Met | Chart note documenting [specific outcome] | | Prescriber attestation of medical necessity | Met | Prescriber letter (Exhibit A) |

A structured, criterion-by-criterion response is consistently the most effective format for PA appeals — it allows Aetna's reviewer to confirm approval without reconstructing your clinical argument from a narrative alone.